This study miss marks a setback for Gilead’s Trodelvy expansion plans, which include both mono and combination therapy ...

The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...

The latest lung cancer development represents a setback for one pathway rather than a verdict on the entire pipeline. Merck ...

Merck’s MRK blockbuster PD-1 inhibitor, Keytruda, approved for several types of cancer, is its key top-line driver, accounting for around 55% of the company’s pharmaceutical sales. Keytruda now holds ...

Merck’s MRK strong position in the oncology market is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor contributes over half of the company’s pharmaceutical ...

Moderna is undergoing a strategic shift, prioritizing infectious disease, oncology, and rare diseases to achieve cash break-even by 2028. 2026 is pivotal, with multiple oncology catalysts—especially ...

Positive opinion also granted for KEYTRUDA as part of a perioperative regimen for the treatment of certain adult patients with resectable locally advanced head and neck squamous cell carcinoma ...